Evaluation of a Potential Therapy for Canine Degenerative Myelopathy

06/01/2017
Breed(s): -All Dogs
Study Type: Clinical Study
Study Location: University of Missouri

The purpose of this study is to evaluate a promising new drug as a treatment for degenerative myelopathy (DM) with hopes to slow disease progression. Dogs will be administered an antisense oligonucleotide (ASO) that will repress the production of the protein, superoxide dismutase 1 (SOD1). The ASO has been tested in a preclinical setting for safety in dogs. The drug will be injected into the spinal fluid at the low lumbar region of the spinal cord. The study will be randomized and double-blinded; neither the investigator nor the pet owner will know whether the dog receives the drug. Eight dogs will receive the drug and four dogs will receive the vehicle. Based on the randomization design, each dog has a 67 percent chance of receiving the therapy. Specific inclusion criteria include early disease stage, relative good health, no significant findings on spinal cord MRI, homozygosity for the SOD1 mutation and study compliance.

More Information

 

Contact Information:
Name: Joan R. Coates, DVM, MS, DACVIM (Neurology)
Email: coatesj@missouri.edu
Phone: 573-882-7821

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $40
  • $60
  • $100
  • $250
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2016 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software